Cemiplimab [CEM3]

To treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy with cemiplimab will be prescribed by a consultant or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. This patient has a histological diagnosis of recurrent or metastatic cervical cancer, and has exhibited disease progression, either whilst receiving, or after treatment with platinum- containing chemotherapy.

Note

Note: The histology must be either squamous, adenocarcinoma, or adenosquamous.

3. This patient has received either ONE or TWO prior lines of systemic treatment for their recurrent/metastatic cervical cancer. Please mark below how many prior lines of treatment have been received:

• ONE prior line
• TWO prior lines

4. The patient has not received prior treatment with an anti PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTL-4) antibody.
5. Treatment with cemiplimab will continue for a total treatment duration of 96 weeks or until disease progression or unacceptable toxicity or withdrawal of patient consent, whichever occurs first.
6. The patient has a performance status (PS) of 0 or 1.
7. The patient has no symptomatically active brain metastases or leptomeningeal metastases.
8. Where a treatment break of more than 12 weeks beyond the expected cycle length is needed, the prescribing clinician will complete a treatment break form to restart treatment, which MUST be approved, before treatment is re-commenced.
9. Cemiplimab will be otherwise used as set out in its Summary of Product Characteristics.

CDF funded From: 23 June 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.404 of the CDF list, downloaded from NHS England’s website on 30 June 2026 at 14:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.